ABT-199 (GDC-0199)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ABT-199 (GDC-0199), covering 2022-12-19 to 2022-12-19. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy [Phase 2]